Behjati Mohaddeseh, Etemadifar Masoud, Abdar Esfahani Morteza
Department of Cardiology, School of Medicine, Cardiovascular Research Center AND Heart Failure Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Iran J Neurol. 2014 Jul 4;13(3):119-26.
Multiple sclerosis (MS) is a chronic auto-immune disease. Most therapeutic strategies for treatment of this disease direct immune modulation and control of inflammatory processes. First-line therapeutic agents showed moderate efficacy and frequent side-effects with moderate efficacy in trials. Their parental administration and limited long-term adherence restrict their efficacy compared with second-line therapies. Fingolimod as a second-line therapeutic agent has been shown to reduce annualized relapse rate, risk of disability progression and inflammatory activity of relapsing MS. Safety and efficacy FTY720: Safety and efficacy issues are the main metrics for judgment of drug efficacy. In this article, we focus on cardiovascular effects of FTY720 treatment. Effect of FTY720 on rate and rhythm, impact of FTY720 on endothelial cells, its atheroprotective effects, its effects on cardiac transplantation outcomes, vascular complications of FTY720, effects of FTY720 on endocrine functions and interaction of FTY720 with cardioactive agents are explained in this review article.
多发性硬化症（MS）是一种慢性自身免疫性疾病。治疗该疾病的大多数治疗策略都旨在进行免疫调节和控制炎症过程。一线治疗药物在试验中显示出中等疗效且副作用频繁。与二线疗法相比，它们的肠胃外给药方式以及有限的长期依从性限制了其疗效。芬戈莫德作为二线治疗药物已被证明可降低复发型MS的年化复发率、残疾进展风险和炎症活动。FTY720的安全性和有效性：安全性和有效性问题是判断药物疗效的主要指标。在本文中，我们重点关注FTY720治疗的心血管效应。本文综述了解释了FTY720对心率和节律的影响、FTY720对内皮细胞的影响、其动脉粥样硬化保护作用、其对心脏移植结果的影响、FTY720的血管并发症、FTY720对内分泌功能的影响以及FTY720与心脏活性药物的相互作用。
